Despite this escalating demand for popular GLP-1 drugs, the prices for some of these products are actually dropping. Dr.
A new crop of evidence — both anecdotal and research based — is pointing to these drugs as a potential option for people ...
The California biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag in combination with tirzepatide ...
It's what most investors want more than anything else from their stocks. Three Motley Fool contributors think they've identified no-brainer growth stocks in the healthcare sector to buy in December.
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker said the Kenosha County, ...
Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial.
Data suggests that dramatic weight loss, including via GLP-1 drugs, could save Americans big bucks in healthcare spending.
STAT reporters Helen Branswell and Allison DeAngelis give updates, respectively, on bird flu and radiopharmaceuticals.
Ozempic and other GLP-1 drugs have surged in popularity, dominating U.S. medication spending in 2023 for their effectiveness in managing diabetes and promoting weight loss. As demand grows, promising ...